Previous 10 | Next 10 |
DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both com...
Gainers: KalVista Pharmaceuticals KALV +134%, Heat Biologics HTBX +70%, Iterum Therapeutics (ITRM) +48%, OrganiGram OGI +47%, Oragenics (OGEN) +24%.Losers: Aeterna Zentaris (AEZS) -27%, Ekso Bionics EKSO -23%, Ocugen OCGN -...
KalVista Pharmaceuticals (KALV) +207% on reporting positive results for KVD900.Comstock Holding Companies (CHCI) +163%.Applied UV (AUVI) +88% after acquiring Airocide Technology Platform.Heat Biologics (HTBX) +47% on announcing positive interim survival data from ongoing HS-110...
Gainers: Anavex Life Sciences (AVXL) +94%, Annovis Bio (ANVS) +50%, Atossa Therapeutics (ATOS) +40%, Cyclerion Therapeutics (CYCN) +40%, Cyclo Therapeutics (CYTH) +33%.Losers: Tyme Technologies (TYME) -36%, Isoray (ISR) -19%, Lannett...
Iterum Therapeutics' (ITRM) underwriter has agreed to increase the size of previous offering and purchase 34,782,609 ordinary shares (or pre-funded warrants) at $1.15/share.Expected gross proceeds are ~$40M.Underwriter's over-allotment is an additional ~5.2M shares. Net proceeds will be used ...
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both com...
Iterum Therapeutics (ITRM) to sell ~8.7M shares at a price of $1.15 per share. Underwriter's an option to purchase up to an additional 1.3M shares.Gross proceeds of ~$10M.Offering is expected to close on or about February 8, 2021.The Company estimates that upon the closing of the offerin...
DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both com...
DUBLIN, Ireland and CHICAGO, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both com...
Gainers: Vir Biotechnology VIR +39%, AIkido Pharma (AIKI) +37%, Edesa Biotech EDSA +34%, Motus GI Holdings (MOTS) +29%, Regional Health Properties (RHE) +24%.Losers: Lipocine (LPCN) -18%, Capricor Therapeutics (CAPR) -17%, Iterum Therapeutics ...
News, Short Squeeze, Breakout and More Instantly...
Iterum Therapeutics plc Company Name:
ITRM Stock Symbol:
NASDAQ Market:
Iterum Therapeutics plc Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...
DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hosp...